RSV Infection
75
10
16
36
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
12 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.7%
5 terminated out of 75 trials
87.8%
+1.3% vs benchmark
4%
3 trials in Phase 3/4
33%
12 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (75)
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools
RSV Burden in Outpatient and Hospital Settings
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.